Incannex Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Highlights:
• Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%,
alpha error probability 0.05) of the study showing a statistically significant benefit for the
psilocybin treatment arm versus the placebo treatment arm at the conclusion of the study
period.
• An independent Data Safety Monitoring Board (DSMB) has reviewed data from Incannex’s
ongoing Phase 2 “PsiGAD” clinical trial and recommends no changes to study design.
• The trial team and DSMB have identified no safety concerns to date.